Daiichi aims for 60 percent growth

Daiichi Sankyo says it's ready for it's close-up. The company got FDA approval last week for a combo remedy for hypertension, Azor, and now it's meeting with its Congressman to talk about adding new jobs at its New Jersey HQ. Perhaps most surprising is its sales-growth target: a whopping 60 percent over the next three years, based on its hopes for Azor and two other meds coming up the pipeline.

Not exactly a household name in the U.S., Daiichi Sankyo has historically developed drugs for licensing to other companies, including Pravachol, a statin sold by Bristol-Myers Squibb; and Levaquin, an antibiotic marketed by Johnson & Johnson. Now, to do more marketing on its own, Daiichi Sankyo has more than doubled its sales force. They'll have to hoof it to meet that ambitious growth target.

- check out Daiichi Sankyo's press release
- read the article in PharmaTimes

Related Articles:
Daiichi Sankyo buys OTC business. Report
Daiichi Sankyo invests in venture fund. Report
Big Pharma brings home the cash, slices payroll. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.